|
The role of cytoreductive radical prostatectomy (cRP) in men with hormone-sensitive, metastatic prostate cancer (mPCA). |
|
|
Honoraria - Amgen; Astellas Pharma; Bayer; Ferring; Ipsen; Janssen-Cilag; Sanofi; Takeda |
Consulting or Advisory Role - Astellas Pharma; Bayer; Johnson & Johnson |
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Ipsen; Johnson & Johnson; Pfizer; Sanofi; Takeda |
Research Funding - Astellas Pharma; Bayer; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |